Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 5.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 20,764 shares of the medical equipment provider’s stock after buying an additional 1,115 shares during the period. Exchange Traded Concepts LLC’s holdings in Hologic were worth $1,497,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HOLX. Sound Income Strategies LLC purchased a new stake in Hologic during the 4th quarter valued at approximately $60,000. Nisa Investment Advisors LLC raised its stake in shares of Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider’s stock worth $4,595,000 after purchasing an additional 19,688 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of Hologic by 80.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 32,588 shares of the medical equipment provider’s stock worth $2,349,000 after purchasing an additional 14,487 shares during the last quarter. Atwood & Palmer Inc. grew its position in Hologic by 0.5% in the 4th quarter. Atwood & Palmer Inc. now owns 357,735 shares of the medical equipment provider’s stock valued at $25,789,000 after buying an additional 1,714 shares during the last quarter. Finally, LaFleur & Godfrey LLC increased its stake in Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider’s stock valued at $9,399,000 after buying an additional 3,655 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.88% of the company’s stock.

Hologic Trading Up 2.5 %

Shares of Hologic stock opened at $72.81 on Tuesday. Hologic, Inc. has a 1 year low of $68.61 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business has a 50 day moving average price of $73.89 and a 200 day moving average price of $78.25. The company has a market capitalization of $16.43 billion, a P/E ratio of 21.86, a P/E/G ratio of 2.43 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 earnings per share. Sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HOLX shares. JPMorgan Chase & Co. lifted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Leerink Partners dropped their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. BNP Paribas raised Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Mizuho decreased their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $88.92.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.